SecBot SecBot
PRESS-RELEASE ·Filed Mar 26, 2026

KMDA

Kamada Ltd.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor ramp-up timing toward full capacity and future EMA approval prospects, which could expand market access. The revenue contribution is modest but strategically significant for Kamada’s plasma supply chain and third-party sales growth.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$8.22
T+0 close · Mar 26, 2026 · via day close
Latest settled
−14.48%
T+60 · $7.03
Vs SPY
−28.43%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 26 $8.22entry
  2. T+1 · 8mo ago −0.85%α +0.83% · $8.15
  3. T+5 · 8mo ago +3.04%α +1.41% · $8.47
  4. T+20 · 7mo ago +0.73%α −9.94% · $8.28
  5. T+60 · 5mo ago −14.48%α −28.43% · $7.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kamada Ltd. announced FDA approval for its San Antonio plasma collection center, enabling commercial sales of normal source plasma. The facility has an annual capacity of 50,000 liters and is expected to generate $8 million to $10 million in annual revenue at full capacity, supporting growth in specialty plasma collection and third-party plasma sales.

Key Financial Metrics

Guidance
$8M-$10M annual at full capacity
initiated

Key Facts

  • FDA approved Kamada's San Antonio plasma collection center following a February 2026 inspection.
  • Facility has 50 donor beds and can collect up to 50,000 liters of plasma annually.
  • Expected annual revenue contribution of $8M–$10M from normal source plasma sales at full capacity.
  • San Antonio center is one of three FDA-approved U.S. plasma centers, alongside Houston and Beaumont.
  • Kamada plans to seek EMA approval for the San Antonio site following FDA clearance.

Financial Impact

Adds $8M–$10M in annual revenue at full capacity from plasma sales

revenueoperating cash flow

Risk Factors

  • Revenue projections are forward-looking and dependent on achieving full collection capacity.
  • Geopolitical risks in the Middle East could disrupt operations in Israel, affecting overall business stability.
  • Regulatory delays possible for EMA approval of the San Antonio center.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3262840

Track record

25 reports on KMDA

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 No price data
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
  4. Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  5. Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  6. Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  7. Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
  8. Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
  9. Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
  10. Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 9h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026